Latest news with #Obesity
Extra.ie
4 days ago
- Health
- Extra.ie
‘Serious alarm' over non-medical sales of weight-loss jabs
A warning from the medicines watchdog that weight-loss drugs such as Ozempic are increasingly becoming available through non-medical routes is a cause of 'serious alarm', Independent TD Carol Nolan has said. The Health Products Regulatory Authority (HPRA) issued an 'urgent warning' in recent days about false claims being made online for sales of counterfeit semaglutide, using the HPRA logo. Last December, RTÉ Investigates examined the sale of unapproved US weight-loss medication in Ireland which revealed the extent of the booming black market in the prescription weight-loss drugs. Medical experts were especially worried about serious health risks from the use of weight-loss pens from Turkey, counterfeit semaglutide pens used as an anti-obesity medication, and unlabelled glass vials openly advertised on social media. A warning from the medicines watchdog that weight-loss drugs such as Ozempic are increasingly becoming available through non-medical routes is a cause of 'serious alarm', Independent TD Carol Nolan has said. Pic: Getty Images Ms Nolan said the most alarming feature of the official response was 'increasing concern around off-licence use and access through unofficial sources, which is not supported and poses significant safety risks'. In queries to the HSE, Ms Nolan said: 'I have been contacted by a number of people who have expressed unease regarding the potential adverse health side-effects and long-term harms that may be induced when a person uses Ozempic medication for weight loss.' In a letter to the embattled organisation, Ms Nolan also asked: 'Has the HSE conducted any research on this matter and is the HSE aware of the apparently growing international literature highlighting adverse outcomes for those who use Ozempic?' One source said: 'It is quite common and easily secured. Often it's a mother-daughter bonding before weddings and holidays' Responding, HSE manager Ann Horgan said: 'I have consulted with the National Clinical Programme (NCP) for Obesity on your question and have been informed the NCP is actively monitoring emerging international evidence on the efficacy and safety of GLP-1 receptor agonists, such as semaglutide. 'The HSE was represented at the European Congress of Obesity in Malaga in May 2025, where the use of obesity medications was discussed. When used as licensed and under clinical supervision, the benefits of semaglutide are considered to outweigh the risks for appropriately selected patients.' The HPRA said last week it had seen a 'surge' in misleading website activity in May alone. It said: 'The websites, which are hosted outside of Ireland by the e-commerce platform Shopify, are being directly prompted to consumers via fake Facebook profiles and ads.' Pic: Getty Images Commenting on the concerns, Ms Nolan said: 'I would urge everyone who is considering going down the Ozempic route to limit their engagement to medical professionals prior to embarking on a course of medication. 'I understand there may be a sense of urgency among some people and a sense that they do not have time to wait in terms of accessing a massively over-burdened primary care and hospital service. But the dangers are real and cannot be ignored. 'I would also highlight our need to dramatically ramp up our detection capacity in terms of taking any illegal consignments of Ozempic out of the public space. 'We are all aware of recent media investigations on this issue and still the problem appears to be escalating. 'That is deeply alarming given the potential for such dire health outcomes for people who may be drawn in by ruthless individuals who couldn't give a damn about what impact unregulated medication access causes
NDTV
27-05-2025
- Health
- NDTV
Chrononutrition Explained: Why Experts Say Meal Timing Matters For Good Health
In recent years, there has been a noticeable shift in the way people approach food. From counting calories to clean eating, from keto to plant-based, more and more individuals are taking their health seriously and actively exploring different diet regimes. The goal? To eat smarter, feel better, and reduce the risk of lifestyle diseases that have become increasingly common. But in this rush towards wellness, the internet is flooded with conflicting information, leaving us utterly confused. Amidst this, many fall into the trap of fad diets that promise quick results but often lack long-term sustainability or scientific backing. That is exactly where chrononutrition comes into the picture. No, it is not another fad that promises a "flat stomach in 10 days". Instead, it takes a more holistic and research-backed approach that looks at when you eat. Turns out, timing may just be as important as what you eat. Let's explore what chrononutrition is all about, why experts are talking about it, and whether it is worth trying. Also Read: 6 Low-Glycemic Index Vegetables To Add To Your Diabetes Diet What Is Chrononutrition? A report on the official website of the Association of UK Dietitians reads that chrononutrition is an emerging field of nutritional science that aims to develop an understanding of how and when we eat may impact our health. One of the initial definitions given in the scientific literature, Cell explained that this concept reflects the basic idea that, "in addition to the amount and content of food, the time of ingestion is also critical for the well-being of an organism". According to several reports, the term chrononutrition was first introduced in the 1980s by Dr. Alain Delabos, a French nutritionist, referring to the timing, frequency, and regularity of meals in relation to your body's circadian rhythm. Also Read: Eating Slowly Can Improve Your Gut Health, Says Expert The Science Behind Chrononutrition Our bodies run on internal clocks known as circadian rhythms, which are regulated by a part of the brain called the suprachiasmatic nucleus (SCN). This master clock responds to light and dark signals. Plus, we also have peripheral clocks in organs like the liver, pancreas, and stomach, which are heavily influenced by when we eat. - Morning: The High Time In the morning, your body is naturally more insulin-sensitive, your digestive enzymes are more active, and your metabolism is at its peak. This makes breakfast the ideal time to consume the majority of your daily calories. A study in the journal Obesity found that people who ate more calories at breakfast and fewer at dinner lost more weight and had better insulin levels than those who did the opposite. - Evening: The Down Time By evening, our body starts slowing down. Eating heavy meals late at night can disrupt digestion, spike blood sugar levels, and interfere with sleep. Research published in the journal Nutrients linked late-night eating to a higher risk of obesity, type 2 diabetes, and heart disease. Also Read: 5 Smart Strategies To Plan A Healthy Food Chart And Lose Weight Does Chrononutrition Actually Work? Chrononutrition sounds logical, but it is not a one-size-fits-all approach for every health problem. The benefits may vary depending on individual lifestyle, food habits and existing health conditions. Pros: It may help manage blood sugar levels. It may aid better digestion and gut health. It may help reduce untimely cravings. It may help manage weight. Challenges: Chrononutrition may be a difficult practice for those with erratic work schedules and a sedentary lifestyle. We agree that the time matters, but it can't replace the need for nutritious food. The quality of food is the key to good health. The Takeaway: Chrononutrition is not about restricting food or chasing the next health trend. Instead, it is about understanding your body's natural rhythms and working with them mindfully. Disclaimer: This content, including advice, provides generic information only. It is in no way a substitute fora qualified medical opinion. Always consult a specialist or your doctor for more information. NDTV does not claim responsibility for this information. Advertisement For the latest food news, health tips and recipes, like us on Facebook or follow us on Twitter and YouTube. Tags: Chrono Nutrition Chrononutrition For Fat Loss Nutrition Health Benefits Show full article Comments
Yahoo
26-05-2025
- Business
- Yahoo
Diet Pills to Surpass USD 4.48 Billion By 2032 Owing to Rising Number of People with Obesity and Increasing Appetite for Non-Invasive Solutions to Weight Management
U.S. Diet Pills Market size to be valued at USD 1.08 Billion in 2032, Project at 12.90% CAGR, Rising Consumption of Prescription Drugs and Increase in the Sales of OTC in Pharmacies and E-commerce. Austin, May 26, 2025 (GLOBE NEWSWIRE) -- Diet Pills Market Size & Growth Analysis: According to SNS Insider, the global Diet Pills Market size stood at USD 1.83 billion in 2024 and is estimated to reach USD 4.48 billion by 2032, with a CAGR of 11.87% from 2025 to 2032. Rising incidence of obesity and sedentary lifestyle on a global level is driving the need for easy to use and efficient weight management methods. Increasing consumer preference for non-surgical non-invasive weight reduction procedures along with growing concern of health hazards associated with obesity is the prediction that is contributing to this a Sample Report of Diet Pills Market@ U.S. Diet Pills Market is estimated to be USD 0.44 billion in 2024 and is projected to exhibit a CAGR of 12.90% over the forecast period (2025-2032). In the U.S., the high uptake of prescription and metabolism-enhancing weight loss drugs, as well as growing OTC demand in drug stores and retail outlets, are driving growth in the U.S. market. Market Overview Diet pills are increasingly growing contoured on the background of increasing trend of obesity, diabetes, and other metabolic diseases worldwide. Worldwide estimates from recent global health data indicate that >40% of adults are overweight or obese, requiring immediate, effective weight-loss interventions. Diet pills present an attractive option to surgery and vigorous exercise. The market too has gained traction with the expansion of healthcare access and with the introduction of digital health platforms, which provides for online consultations, prescriptions and consumer awareness about weight-loss treatments. The introduction of product innovations, including appetite suppressant/metabolism booster combination products, non-stimulant options or plant-based capsules, has increased consumer use in different demographic target groups, including the young and those in whom there may be contraindications to conventional treatment. In an era of preventive health and wellness, diet pills are included in overall wellness programs. Major Players Analysis Listed in this Report are: Iovate Health Sciences Inc. Zoller Laboratories Cortislim Nanjing Chang'ao Pharmaceutical Co. Vivus Inc. Orexigen Therapeutics GlaxoSmithKline Pharmaceuticals Ltd. Gelesis Inc. Herbalife International Amway Corp. and others in the final report Diet Pills Market Report Scope Report Attributes Details Market Size in 2024 US$ 1.83 billion Market Size by 2032 US$ 4.48 billion CAGR CAGR of 11.87% From 2025 to 2032 Base Year 2023 Forecast Period 2025-2032 Historical Data 2021-2023 Key Regional Coverage North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) Segment Analysis By Product: In 2024, prescription-based drugs held the largest share of the market at 62%, owing to clinical efficacy, regulatory backing, and physician trust in managing moderate to severe obesity. These drugs are often the first line of treatment for individuals with comorbidities like diabetes and hypertension. On the other hand, herbal remedies have emerged as the fastest-growing product segment. Their rise is driven by a global trend toward natural and plant-based healthcare solutions, especially among younger consumers and those wary of synthetic chemicals. By Application: Appetite-controlling pills accounted for around 48% of the market share in 2024, making them the dominant application. These pills are preferred for their ability to help regulate food intake and reduce binge-eating behaviors, which is common in sedentary urban populations. However, metabolism-boosting pills are seeing the highest growth rate. Consumers increasingly favor them for their perceived ability to burn calories efficiently, especially when combined with minimal physical activity, which aligns with the busy lifestyles of working professionals. By Distribution Channel: Retail pharmacies led the distribution channels with 53% of the market share in 2024. These outlets are accessible and trusted by consumers, offering both OTC and prescription-based diet pills. Meanwhile, hospital pharmacies are growing rapidly as healthcare providers increasingly prescribe weight loss medications in clinical settings. The credibility and availability of post-consultation guidance in hospitals make them the fastest-growing channel. Need Any Customization Research on Diet Pills Market, Enquire Now@ Diet Pills Market Segmentation By Product Type Prescription-Based Drugs Over-the-Counter Drugs Herbal Supplements By Application Metabolism Raising Pills Fat Blocking Pills Appetite Controlling Pills By Distribution Channel Hospital Pharmacy Retail Pharmacy Drug Stores Regional Analysis Asia Pacific dominated the global diet pills market in 2024, driven by rising obesity rates in densely populated countries like China and India, growing disposable income, and rapid urbanization. The regional market benefits from both traditional medicine integration and increasing acceptance of Western pharmacological treatments. North America emerged as the second-largest regional market, fueled by the high prevalence of obesity, strong pharmaceutical infrastructure, and widespread insurance coverage for prescription weight-loss medications. The U.S. market, in particular, is witnessing a surge in consumer spending on lifestyle-enhancing drugs and an increase in online pharmacy adoption. Recent Developments In March 2025, Eli Lilly reported successful mid-stage trials for orforglipron, its once-daily oral weight loss drug. The pill demonstrated significant weight reduction, potentially rivaling injectable GLP-1 therapies. In April 2025, Pfizer halted development of its oral weight-loss candidate, danuglipron, due to adverse side effects in Phase 2 trials, indicating market risks in oral anti-obesity drug development. In November 2024, Nature's Way released SlimBiotic Naturals, an herbal diet supplement containing green coffee bean extract and garcinia cambogia, entering the fast-growing plant-based pill market. In September 2024, PhenQ introduced PhenQ PM, a nighttime fat-burning formula to complement its popular daytime version, appealing to 24-hour weight management consumers. Statistical Insights and Trends Reporting Over 1 billion adults were overweight, with more than 650 million classified as obese worldwide. This demographic forms the core consumer base for diet pills. North America accounted for over 40% of global prescription diet pill sales, driven by advanced healthcare infrastructure and favorable regulatory support. The number of diet pills sold annually is projected to nearly triple from 1.2 billion units in 2020 to over 3.4 billion units by 2032, with strong demand from Asia Pacific. Consumer out-of-pocket expenditure on weight-loss supplements and prescription pills accounted for 65% of total spending in emerging economies due to limited insurance coverage. Online sales of diet pills witnessed a 45% year-on-year growth, especially in urban markets, due to increasing e-commerce penetration and discreet delivery a Single-User PDF of Diet Pills Market Analysis & Outlook Report 2024-2032@ Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 5.1 Obesity and Overweight Prevalence (2024), by Region 5.2 Diet Pills Consumption and Usage Trends (2024), by Region 5.3 Prescription vs. OTC Diet Pills Trends (2021–2032) 5.4 Consumer Spending on Weight Management Products, by Region (2024) 5.5 Internet & E-Commerce Sales Trends for Diet Pills (2021–2024) 5.6 Regulatory Trends and Product Approvals (Recent Years) 6. Competitive Landscape 7. Diet Pills Market by Product Type 8. Diet Pills Market by Application 9. Diet Pills Market by Distribution Channel 10. Regional Analysis 11. Company Profiles 12. Use Cases and Best Practices 13. Conclusion Related Reports U.S. Anti-Obesity Drugs Market Set to Soar, Reaching $10.28 Billion by 2032 at 24.07% CAGR. Global Weight Loss Drugs Market to Skyrocket to $50.26 Billion by 2032, Growing at 43.73% CAGR. Weight Loss Supplements Market to Hit $161.03 Billion by 2030, Growing at 16.9% CAGR. Weight Loss Devices Market Forecasted to Reach $8.50 Billion by 2032, Growing at 6.60% CAGR. About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Post
13-05-2025
- Health
- New York Post
Most obese US states revealed in new report — did yours make the list?
It's a heavy truth to bear. US News has weighed in on America's ever-expanding waistline, ranking the country's most obese states — and the results may leave you reconsidering that greasy burrito. 3 US News' new 2025 Best States report ranks the country's most obese states. Creativa Images – Topping the list is West Virginia, where nearly 41% of adults are classified as obese, giving the Mountain State a not-so-slim lead over its neighbors. Next are Arkansas, Mississippi, Louisiana, Alabama, Oklahoma, Iowa, Kentucky, Indiana and Tennessee — where the obesity rate is as high as 37.8%. Meanwhile, Colorado — famous for its craft breweries but also for its plethora of outdoor activities — took the lead in states with the lowest obesity rate, coming in at 24.6%. Following the Centennial State are Hawaii, Massachusetts, California, New York, New Jersey, Vermont, Connecticut, Florida and Montana. 3 Colorado took the lead in states with the lowest obesity rate, weighing in at 24.6%. – The findings indicate that — even in the least obese state — more than two out of 10 residents are considered obese, lending credence to the belief that America is fatter than ever. Prior to 2013, no state in the US had an adult obesity prevalence at or above 35%, according to the Centers for Disease Control and Prevention. Clearly, much has changed. 3 The CDC's Adult Obesity Prevalence Map, last updated in September 2024. CDC Obesity is defined as having a body mass index of 30 or higher — and it is associated with an increased risk of sleep apnea, infertility, depression, heart disease, diabetes and certain cancers. The World Health Organization officially declared obesity a global epidemic in 1997, noting that rates had nearly tripled since 1975 — which is when experts believe the epidemic began. What has remained a hotly debated mystery is why the epidemic rages on, with many pointing the finger at lifestyle factors such as increases in ultra-processed foods and sedentary behavior. The good news is that while technology may be making us fatter, TikTok nutrition hacks and trendy weight loss drugs offer novel ways to win the battle of the bulge.
Yahoo
13-05-2025
- Health
- Yahoo
New Retrospective Study Reports Significantly Reduced Post-Operative GERD Rates with the Titan SGS™ Stapler from Teleflex Compared with Multi-Fire Staplers in Sleeve Gastrectomy
Data also demonstrate significantly lower rates of postoperative reflux and decreased incidence of de novo gastroesophageal reflux disease (GERD) without affecting total weight loss at 1-year*, and shorter average hospital length of stay (LOS) associated with use of the Titan SGS™ Stapler compared with multi-fire staplers1 WAYNE, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the publication of a new retrospective analysis of clinical data associating the use of the Titan SGS™ Stapler with reduced rates of post-operative GERD following robotic-assisted laparoscopic sleeve gastrectomy (LSG) compared with traditional multi-fire surgical staplers.1 The retrospective study comprised 257 patients who underwent robot-assisted sleeve gastrectomy using the Titan SGS™ Stapler or multiple fires of a traditional linear stapler between 2016 and 2023. All procedures included in the study were performed by a single surgeon.1 The study has been published online in Obesity Surgery.1 Sleeve gastrectomy is the most common weight-loss surgery in the U.S.2 While the procedure is associated with a low rate of adverse events during and following surgery, a 2024 review of 109 studies found 'a persistent concern for worsening and de novo GERD' after sleeve gastrectomy.3 Pouch shapes based on anatomical landmarks have previously been shown to help reduce the incidence of GERD4 but highly variable surgical techniques and multiple stapler fires yield inconsistent pouch anatomy.5 Consequently, one study found that bariatric surgeons have been able to achieve the ideal tubular sleeve anatomy less than 40% of the time, resulting in inconsistent patient outcomes, including GERD and nausea.5 'Improving clinical outcomes for patients — including the development of post-operative GERD — may be important for wider adoption of bariatric surgery, which remains the most effective and durable obesity treatment,' said Forrest Ringold, MD, FACS, SAGES, an expert in bariatric and robotic surgery at the Surgical Association of Mobile and senior researcher on the publication. 'This study shows that GERD was less common in LSG procedures that used the Titan SGS™ Stapler. I believe this is because the 23cm single-fire Titan SGS™ Stapler is intentionally designed to enable more consistent and symmetrical sleeve anatomy and to provide reproducible pouch anatomies from patient to patient.6 This study adds to a growing body of evidence supporting the potentially enhanced perioperative benefits linked to the Titan SGS™ Stapler in sleeve gastrectomy.' The Titan SGS™ Stapler is the first and only single-fire, surgical stapler designed and indicated specifically for sleeve gastrectomy pouch creation.6 As the only stapler to provide a 23cm staple line — the industry's longest continuous staple cutline —the Titan SGS™ Stapler is designed to provide an ideal tubular surgical sleeve anatomy that is a consistent shape, free of kinks, twists, or spirals, improving the potential to resolve GERD and nausea.4,7 The publication reports retrospective observational data that at one-year post-procedure, significantly fewer patients in the Titan SGS™ Stapler cohort reported having GERD (7.1%) compared with the multi-fire cohort (26.4%) (p = 0.002) and significantly fewer patients in the Titan SGS™ Stapler cohort developed de novo GERD (1.8%) compared with the multi-fire cohort (10.9%) (p = 0.005). Additionally, more patients in the Titan SGS™ Stapler cohort who had GERD prior to the procedure saw resolution of this condition, compared to the multi-fire cohort (25% vs. 10.9%, p = 0.005). Notably, the improvements in GERD outcomes linked to the Titan SGS™ Stapler were achieved without a significant difference in weight loss at 1 year between the two cohorts (multiple-fire: 22.4% ± 0.7%, single-fire: 22.0% ± 1.7%, p = 0.8).* 'The Titan SGS™ Stapler was developed to enable more consistent and symmetrical sleeve anatomy because we believe that sleeve shape significantly contributes to sleeve gastrectomy efficacy and safety outcomes,' said James Ferguson, President and General Manager, Surgical, at Teleflex. 'The study's authors hypothesize that the improved GERD outcomes reported in the Titan SGS™ Stapler cohort may be because the 23cm single-fire continuous staple line without overlapping staple firings 'results in less kinking along the sleeve staple line, which prevents inadvertent narrowing'. This suggests that consistent sleeve shape may play a role in reducing GERD.' In previous retrospective studies, the Titan SGS™ Stapler has been associated with significantly reduced operative times,8 less post-op nausea and vomiting7-8 and the potential for increased operational efficiencies and significant reductions in LOS and readmissions.4,6-10 For more information about the Titan SGS™ Stapler or to learn more about the Titan Sleeve™ Technique, visit Learn about the exciting innovation behind the Titan SGS™ Stapler at: Innovation Story. About TeleflexAs a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare. Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose. At Teleflex, we are empowering the future of healthcare. For more information, please visit Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. Teleflex, the Teleflex logo, Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, Titan SGS, Titan Sleeve, UroLift and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. Dr. Morton and Dr. Ringold, two of the authors of the study, are paid consultants of Teleflex Incorporated. *The Titan SGS™ Stapler is intended for longitudinal transection and resection of gastric tissue for sleeve gastrectomy pouch creation. The Titan SGS™ Stapler is one of several instruments used by surgeons during sleeve gastrectomy procedures and has been cleared by FDA based on clinical studies and other data establishing its performance for this purpose. The Titan SGS™ Stapler is not indicated for weight loss. © 2025 Teleflex Incorporated. All rights reserved. MC-010771 References _______________1Ying L, Rutledge R, Butensky S, et al. Does stapling platform influence robotic sleeve gastrectomy postoperative outcomes?. Obes Surg. 2025; doi: 10.1007/s11695-025-07855-z. 2 Angrisani L, Santonicola A, Iovino P, et al. Bariatric Surgery Worldwide 2013. Obes Surg. 2015;25:1822–1832. doi: 10.1007/s11695-015-1657-z.3 Masood M, Low DE, Deal SB, Kozarek RA. Current management and treatment paradigms of gastroesophageal reflux disease following sleeve gastrectomy. J Clin Med. 2024;13(5):1246. doi: 10.3390/jcm130512464 Thompson J, Dhar V, Hanseman D, et al. Anatomy-based laparoscopic sleeve gastrectomy reduces gastroesophageal reflux disease compared to laparoscopic sleeve gastrectomy with bougie. Surgery for Obesity and Related Diseases, 2017;13(10). doi: 10.1016/ Toro, J., Lin, E., Patel, A., et al. Association of Radiographic Morphology with Early Gastroesophageal Reflux Disease and Satiety Control after Sleeve Gastrectomy. Journal of the American College of Surgeons, 2014;219(3), 430–438. doi: 10.1016/ 6 U.S. Food and Drug Administration. 510(k) Premarket Notification: K210278. Published April 28, 2021.7 Standard Bariatrics, Inc. Multisite comparison of Titan SGS to existing surgical staplers in sleeve gastrectomy; 2022. Qualitee 360 Report. Unpublished raw data. Retrieved from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) database.8 Fritz GD, Sharrak A, Aubrey J, et al. Perioperative outcomes using single-fire stapler. Obes Surg. 2024;34(9):3553-3560. doi:10.1007/s11695-024-07357-4. 9 Salyer CE, Thompson J, Hoffman A, et al. (2022). Multisite Study of Titan SGS Stapler in longitudinal gastric resection. Surg Endosc. 2021;35(7):4016-4021. doi:10.1007/s00464-020-07858-0.10 Varban OA, Niemann A, Stricklen A, et al. Far from Standardized: Using Surgical Videos to Identify Variation in Technique for Laparoscopic Sleeve Gastrectomy. J Laparoendosc Adv Surg Tech A.2017;27(8):761–767. doi:10.1089/lap.2017.0184. Contacts:TeleflexLawrence KeuschVice President, Investor Relations and Strategy in to access your portfolio
